AU2018234632B2 - Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal - Google Patents

Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal Download PDF

Info

Publication number
AU2018234632B2
AU2018234632B2 AU2018234632A AU2018234632A AU2018234632B2 AU 2018234632 B2 AU2018234632 B2 AU 2018234632B2 AU 2018234632 A AU2018234632 A AU 2018234632A AU 2018234632 A AU2018234632 A AU 2018234632A AU 2018234632 B2 AU2018234632 B2 AU 2018234632B2
Authority
AU
Australia
Prior art keywords
yap
pro
gln
yap5sa
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018234632A
Other languages
English (en)
Other versions
AU2018234632A1 (en
Inventor
John Leach
James F. Martin
Tanner MONROE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2018234632A1 publication Critical patent/AU2018234632A1/en
Application granted granted Critical
Publication of AU2018234632B2 publication Critical patent/AU2018234632B2/en
Priority to AU2024219497A priority Critical patent/AU2024219497B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
AU2018234632A 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal Active AU2018234632B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024219497A AU2024219497B2 (en) 2017-03-14 2024-09-09 Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471204P 2017-03-14 2017-03-14
US62/471,204 2017-03-14
PCT/US2018/022496 WO2018170172A1 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219497A Division AU2024219497B2 (en) 2017-03-14 2024-09-09 Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal

Publications (2)

Publication Number Publication Date
AU2018234632A1 AU2018234632A1 (en) 2019-10-03
AU2018234632B2 true AU2018234632B2 (en) 2024-06-13

Family

ID=63523973

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018234632A Active AU2018234632B2 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal
AU2024219497A Active AU2024219497B2 (en) 2017-03-14 2024-09-09 Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219497A Active AU2024219497B2 (en) 2017-03-14 2024-09-09 Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal

Country Status (10)

Country Link
US (3) US11484553B2 (https=)
EP (1) EP3595642A4 (https=)
JP (3) JP2020513810A (https=)
CN (2) CN110520112A (https=)
AU (2) AU2018234632B2 (https=)
BR (1) BR112019018912A2 (https=)
CA (1) CA3056231A1 (https=)
IL (2) IL269187B2 (https=)
MX (2) MX2019010986A (https=)
WO (1) WO2018170172A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145890A1 (en) * 2017-06-01 2021-05-20 Baylor College Of Medicine Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
WO2021119030A1 (en) * 2019-12-09 2021-06-17 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20210324412A1 (en) * 2020-04-15 2021-10-21 University Of Southern California Activation of yap signaling for sensory receptor regeneration
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
US20230193267A1 (en) * 2021-10-19 2023-06-22 Animatus Biosciences, Inc. Cardiac cell proliferation by administering inhibitors of sav1, nf2, mob1 and/or mutant srf
IL322204A (en) * 2023-02-10 2025-09-01 Baylor College Medicine Use of mutant yap for improving cardiac function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
TW563139B (en) 2000-11-30 2003-11-21 Nec Tokin Corp Magnetic core including magnet for magnetic bias and inductor component using the same
US8140593B2 (en) * 2008-05-15 2012-03-20 Microsoft Corporation Data viewer management
KR101057116B1 (ko) * 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10772974B2 (en) * 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途
EP3105329A1 (en) * 2014-02-11 2016-12-21 Institut Pasteur Treatment of cardiac diseases with modulators of the hippo pathway
WO2016044096A1 (en) * 2014-09-16 2016-03-24 Albert Einstein College Of Medicine Of Yeshiva University Repopulation of organs and tissues using a yap-ert2 fusion protein
GB201819659D0 (en) * 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse

Also Published As

Publication number Publication date
JP2024073571A (ja) 2024-05-29
AU2018234632A1 (en) 2019-10-03
WO2018170172A1 (en) 2018-09-20
IL269187B2 (en) 2024-04-01
US12138284B2 (en) 2024-11-12
US20230063735A1 (en) 2023-03-02
US20250073276A1 (en) 2025-03-06
IL308112B2 (en) 2025-01-01
EP3595642A1 (en) 2020-01-22
JP2022164658A (ja) 2022-10-27
EP3595642A4 (en) 2021-05-26
CN110520112A (zh) 2019-11-29
JP2020513810A (ja) 2020-05-21
MX2022011881A (es) 2022-11-09
CA3056231A1 (en) 2018-09-20
BR112019018912A2 (pt) 2020-04-14
US20200016212A1 (en) 2020-01-16
US11484553B2 (en) 2022-11-01
AU2024219497A1 (en) 2024-10-03
JP7461071B2 (ja) 2024-04-03
IL269187A (en) 2019-11-28
CN116003564A (zh) 2023-04-25
IL308112A (en) 2023-12-01
MX2019010986A (es) 2020-02-05
AU2024219497B2 (en) 2025-08-14
IL308112B1 (en) 2024-09-01
IL269187B1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
AU2024219497B2 (en) Dominant active yap, a hippo effector, induces chromatin accessibility and cardiomyocyte renewal
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
US20190256846A1 (en) Modulation of tjp1 expression to regulate regeneration of heart cells
Li et al. Deletion of ASPP1 in myofibroblasts alleviates myocardial fibrosis by reducing p53 degradation
US20210205300A1 (en) Polycomb inhibitors and uses thereof
US20240197760A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
US20210145890A1 (en) Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
Nayakanti Role of FoxO3 transcription factor in right ventricular remodeling and failure
US20260015615A1 (en) Spermatogenesis alteration
Cruz Cruz The Role of MDM2 in Mouse Development and its Implication in the Pathogenesis of Cancer and Developmental Diseases
Cruz The Role of MDM2 in Mouse Development and its Implication in the Pathogenesis of Cancer and Developmental Diseases
HK40057503A (en) Compositions and methods of using tyrosine kinase inhibitors
CA2974958C (en) Compositions and methods of using tyrosine kinase inhibitors
Kumar et al. An Intermittent Fasting Mimetic Drives Plasticity Via an Adaptive ER Stress-ATF4 Pathwayand Elicits Stroke Recovery and Alzheimer's Resilience

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ DOMINANT ACTIVE YAP, A HIPPO EFFECTOR, INDUCES CHROMATIN ACCESSIBILITY AND CARDIOMYOCYTE RENEWAL

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ DOMINANT ACTIVE YAP, A HIPPO EFFECTOR, INDUCES CHROMATIN ACCESSIBILITY AND CARIOMYOCYTE RENEWAL

FGA Letters patent sealed or granted (standard patent)